{"transactions":[{"id":1263240,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:55:25.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":84700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025."}],"balance_after":84700,"derivative":{"exercise_price":3.18,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":84700},"source":{"system":"sec-edgar","filing":"0001662579-25-000020","document":"wk-form4_1739915720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000020/wk-form4_1739915720.xml","form_type":"4"}},{"id":1263239,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:55:25.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2914,"price":3.18,"value":9266.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":107939,"source":{"system":"sec-edgar","filing":"0001662579-25-000020","document":"wk-form4_1739915720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000020/wk-form4_1739915720.xml","form_type":"4"}},{"id":1263238,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:55:25.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":56500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026."}],"balance_after":110853,"source":{"system":"sec-edgar","filing":"0001662579-25-000020","document":"wk-form4_1739915720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000020/wk-form4_1739915720.xml","form_type":"4"}},{"id":1263237,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:55:25.000Z","date":"2025-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":2135,"price":3.2,"value":6832.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":54353,"source":{"system":"sec-edgar","filing":"0001662579-25-000020","document":"wk-form4_1739915720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257925000020/wk-form4_1739915720.xml","form_type":"4"}},{"id":1368139,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2024-11-12T21:17:13.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":10500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001662579-24-000101","document":"wk-form4_1731446224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000101/wk-form4_1731446224.xml","form_type":"4"}},{"id":1368138,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-11-12T21:17:13.000Z","date":"2024-11-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1102,"price":6.04,"value":6656.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":56488,"source":{"system":"sec-edgar","filing":"0001662579-24-000101","document":"wk-form4_1731446224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000101/wk-form4_1731446224.xml","form_type":"4"}},{"id":1368137,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-11-12T21:17:13.000Z","date":"2024-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":57590,"source":{"system":"sec-edgar","filing":"0001662579-24-000101","document":"wk-form4_1731446224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000101/wk-form4_1731446224.xml","form_type":"4"}},{"id":1404566,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2024-09-17T21:11:56.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":14250,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001662579-24-000079","document":"wk-form4_1726607510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000079/wk-form4_1726607510.xml","form_type":"4"}},{"id":1404565,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-09-17T21:11:56.000Z","date":"2024-09-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":661,"price":6.36,"value":4203.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":53840,"source":{"system":"sec-edgar","filing":"0001662579-24-000079","document":"wk-form4_1726607510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000079/wk-form4_1726607510.xml","form_type":"4"}},{"id":1404564,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-09-17T21:11:56.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":54501,"source":{"system":"sec-edgar","filing":"0001662579-24-000079","document":"wk-form4_1726607510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000079/wk-form4_1726607510.xml","form_type":"4"}},{"id":1585913,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:19:08.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022."}],"balance_after":90000,"derivative":{"exercise_price":19,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001662579-24-000024","document":"wk-form4_1709943540.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000024/wk-form4_1709943540.xml","form_type":"4"}},{"id":1585912,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:19:08.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022."}],"balance_after":0,"derivative":{"exercise_price":22.71,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001662579-24-000024","document":"wk-form4_1709943540.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000024/wk-form4_1709943540.xml","form_type":"4"}},{"id":1585911,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:19:08.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":84850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021."}],"balance_after":84850,"derivative":{"exercise_price":19,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":84850},"source":{"system":"sec-edgar","filing":"0001662579-24-000024","document":"wk-form4_1709943540.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000024/wk-form4_1709943540.xml","form_type":"4"}},{"id":1585910,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-09T00:19:08.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":84850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021."}],"balance_after":0,"derivative":{"exercise_price":45.54,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":84850},"source":{"system":"sec-edgar","filing":"0001662579-24-000024","document":"wk-form4_1709943540.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000024/wk-form4_1709943540.xml","form_type":"4"}},{"id":1640529,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:07:14.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":122800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024."}],"balance_after":122800,"derivative":{"exercise_price":7.31,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":122800},"source":{"system":"sec-edgar","filing":"0001662579-24-000018","document":"wk-form4_1708034815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000018/wk-form4_1708034815.xml","form_type":"4"}},{"id":1640528,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:07:14.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":27300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025."}],"balance_after":52251,"source":{"system":"sec-edgar","filing":"0001662579-24-000018","document":"wk-form4_1708034815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000018/wk-form4_1708034815.xml","form_type":"4"}},{"id":1640527,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:07:14.000Z","date":"2024-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1735,"price":6.53,"value":11329.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") and does not represent a sale by the Reporting Person."}],"balance_after":24951,"source":{"system":"sec-edgar","filing":"0001662579-24-000018","document":"wk-form4_1708034815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257924000018/wk-form4_1708034815.xml","form_type":"4"}},{"id":1776830,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-19T23:22:39.000Z","date":"2023-09-18","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on September 18, 2025, subject to the Reporting Person's continued service on such date."}],"balance_after":120000,"derivative":{"exercise_price":2.15,"expiration_date":"2033-09-17","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001662579-23-000098","document":"wk-form4_1695165751.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000098/wk-form4_1695165751.xml","form_type":"4"}},{"id":1791698,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-08-31T20:12:31.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":16500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001662579-23-000085","document":"wk-form4_1693512739.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000085/wk-form4_1693512739.xml","form_type":"4"}},{"id":1791697,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-08-31T20:12:31.000Z","date":"2023-08-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":661,"price":2.93,"value":1936.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":26686,"source":{"system":"sec-edgar","filing":"0001662579-23-000085","document":"wk-form4_1693512739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000085/wk-form4_1693512739.xml","form_type":"4"}},{"id":1791696,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-08-31T20:12:31.000Z","date":"2023-08-30","kind":"exercise","planned":false,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":27347,"source":{"system":"sec-edgar","filing":"0001662579-23-000085","document":"wk-form4_1693512739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000085/wk-form4_1693512739.xml","form_type":"4"}},{"id":2013148,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:45:49.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023."}],"balance_after":90000,"derivative":{"exercise_price":5.67,"expiration_date":"2033-02-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001662579-23-000038","document":"wf-form4_167649753180992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000038/wf-form4_167649753180992.xml","form_type":"4"}},{"id":2013147,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-15T21:45:49.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024."}],"balance_after":25097,"source":{"system":"sec-edgar","filing":"0001662579-23-000038","document":"wf-form4_167649753180992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000038/wf-form4_167649753180992.xml","form_type":"4"}},{"id":2038211,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2023-02-01T21:09:12.000Z","date":"2023-01-30","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":18750,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001662579-23-000019","document":"wf-form4_167528573105921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000019/wf-form4_167528573105921.xml","form_type":"4"}},{"id":2038210,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-01T21:09:12.000Z","date":"2023-01-30","kind":"tax_withholding","acquired":false,"shares":1301,"price":7.78,"value":10121.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person."}],"balance_after":5097,"source":{"system":"sec-edgar","filing":"0001662579-23-000019","document":"wf-form4_167528573105921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000019/wf-form4_167528573105921.xml","form_type":"4"}},{"id":2038209,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-02-01T21:09:12.000Z","date":"2023-01-30","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":6398,"source":{"system":"sec-edgar","filing":"0001662579-23-000019","document":"wf-form4_167528573105921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000019/wf-form4_167528573105921.xml","form_type":"4"}},{"id":2232217,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-06-14T20:45:57.000Z","date":"2022-05-26","kind":"tax_withholding","acquired":false,"shares":1102,"price":7.01,"value":7725.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":2648,"source":{"system":"sec-edgar","filing":"0001209191-22-036718","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122036718/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-27"}},{"id":2252697,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2022-05-27T20:16:06.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":22500,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001209191-22-032515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122032515/doc4.xml","form_type":"4"}},{"id":2252696,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-05-27T20:16:06.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":3750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":3750,"source":{"system":"sec-edgar","filing":"0001209191-22-032515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122032515/doc4.xml","form_type":"4"}},{"id":2391235,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance Restricted Stock Units","published_at":"2022-02-16T21:30:28.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance restricted stock unit (\"PRSU\") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones."}],"balance_after":26250,"derivative":{"expiration_date":"2025-02-28","underlying":"Common Stock","underlying_shares":26250},"source":{"system":"sec-edgar","filing":"0001209191-22-010207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122010207/doc4.xml","form_type":"4"}},{"id":2391234,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-16T21:30:28.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022."}],"balance_after":90000,"derivative":{"exercise_price":22.71,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-010207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919122010207/doc4.xml","form_type":"4"}},{"id":2570320,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-14T20:08:34.000Z","date":"2021-09-10","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"20% of this option vested and became exercisable on July 1, 2021, with the remainder vesting in 16 equal quarterly installments thereafter."}],"balance_after":271321,"derivative":{"exercise_price":4.98,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-055881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121055881/doc4.xml","form_type":"4"}},{"id":2570319,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-14T20:08:34.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":12500,"price":50,"value":625000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-055881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121055881/doc4.xml","form_type":"4"}},{"id":2570318,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-09-14T20:08:34.000Z","date":"2021-09-10","kind":"exercise","acquired":true,"shares":12500,"price":4.98,"value":62250.0,"ownership":{"direct":true},"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001209191-21-055881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121055881/doc4.xml","form_type":"4"}},{"id":2619662,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-02T22:49:11.000Z","date":"2021-07-29","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"20% of this option vested and became exercisable on July 1, 2021, with the remainder vesting in 16 equal quarterly installments thereafter."}],"balance_after":283821,"derivative":{"exercise_price":4.98,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-049120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121049120/doc4.xml","form_type":"4"}},{"id":2619661,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-08-02T22:49:11.000Z","date":"2021-07-29","kind":"sale","acquired":false,"shares":12500,"price":45,"value":562500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-049120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121049120/doc4.xml","form_type":"4"}},{"id":2619660,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-08-02T22:49:11.000Z","date":"2021-07-29","kind":"exercise","acquired":true,"shares":12500,"price":4.98,"value":62250.0,"ownership":{"direct":true},"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001209191-21-049120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121049120/doc4.xml","form_type":"4"}},{"id":2858232,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-16T21:15:33.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":84850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021."}],"balance_after":84850,"derivative":{"exercise_price":45.54,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":84850},"source":{"system":"sec-edgar","filing":"0001209191-21-010708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662579/000120919121010708/doc4.xml","form_type":"4"}},{"id":3159630,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:06:27.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":12,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001694187-20-000064","document":"wf-form4_158881356966436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000064/wf-form4_158881356966436.xml","form_type":"4"}},{"id":3159629,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:06:27.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":6.13,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001694187-20-000064","document":"wf-form4_158881356966436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000064/wf-form4_158881356966436.xml","form_type":"4"}},{"id":3159628,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Common Stock","published_at":"2020-05-06T21:06:27.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":161821,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive 0.063 (the \"Exchange Ratio\") of American Depositary Shares of BioNTech (\"BioNTech ADS\") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 141,250 restricted stock units (each, an \"RSU\") held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive 0.063 (the \"Exchange Ratio\") of American Depositary Shares of BioNTech (\"BioNTech ADS\") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 141,250 restricted stock units (each, an \"RSU\") held by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001694187-20-000064","document":"wf-form4_158881356966436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000064/wf-form4_158881356966436.xml","form_type":"4"}},{"id":3238363,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Common Stock","published_at":"2020-03-02T18:39:44.000Z","date":"2020-02-29","kind":"tax_withholding","acquired":false,"shares":2845,"price":1.5,"value":4267.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on February 27, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 29, 2020."}],"balance_after":161821,"source":{"system":"sec-edgar","filing":"0001694187-20-000030","document":"wf-form4_158319236693881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000030/wf-form4_158319236693881.xml","form_type":"4"}},{"id":3243997,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Common Stock","published_at":"2020-02-27T18:21:20.000Z","date":"2020-02-25","kind":"tax_withholding","acquired":false,"shares":5334,"price":1.51,"value":8054.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on November 25, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 25, 2020."}],"balance_after":164666,"source":{"system":"sec-edgar","filing":"0001694187-20-000013","document":"wf-form4_158284566350478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000013/wf-form4_158284566350478.xml","form_type":"4"}},{"id":3312634,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Common Stock","published_at":"2020-01-13T17:27:19.000Z","date":"2020-01-12","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ms. Siegel was awarded 65,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on January 31, 2021 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":170000,"source":{"system":"sec-edgar","filing":"0001694187-20-000008","document":"wf-form4_157895442165741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000008/wf-form4_157895442165741.xml","form_type":"4"}},{"id":3360056,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Common Stock","published_at":"2019-11-25T17:25:28.000Z","date":"2019-11-25","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ms. Siegel was awarded 75,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest quarterly over one year, subject to the Reporting Person's continued service, with the first tranche vesting on February 25, 2020. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":105000,"source":{"system":"sec-edgar","filing":"0001694187-19-000078","document":"wf-form4_157472071053026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418719000078/wf-form4_157472071053026.xml","form_type":"4"}},{"id":3623346,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-01T18:20:21.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019."}],"balance_after":60000,"derivative":{"exercise_price":6.13,"expiration_date":"2029-02-26","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001694187-19-000015","document":"wf-form4_155148240739994.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418719000015/wf-form4_155148240739994.xml","form_type":"4"}},{"id":3623345,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":49049,"kind":"person","name":"Siegel Jolie","position":1,"cik":"0001768223","reported_name":"Siegel Jolie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, General Counsel"}}],"security":"Common Stock","published_at":"2019-03-01T18:20:21.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Ms. Siegel was awarded 30,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001694187-19-000015","document":"wf-form4_155148240739994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418719000015/wf-form4_155148240739994.xml","form_type":"4"}}]}